ClinicalTrials.gg

Program

sefaxersen

Its studies are mostly in Glomerulonephritis, IGA, led by Hoffmann-La Roche.

Furthest: phase 3, since Mar 22, 20231 company-led study, 1 open or runningNext primary completion: May 25, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche11 open or runningphase 3since Mar 22, 2023Mar 22, 2023May 25, 2028phase 3 · NCT05797610
  • Named in Hoffmann-La Roche’s own pipeline as RG6299 sefaxersen (Ionis), phase 3, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 22, 2023First study: phase 3 study in Glomerulonephritis, IGAFirst studyNCT05797610 · 459 enrolled · United States, Argentina, Australia and more
  2. Oct 5, 2026Primary completion moved from 2026-08-31 to 2028-05-25Date moved laterphase 3 · +21 months · NCT05797610

Ahead

  1. May 25, 2028Primary completion: phase 3 study in Glomerulonephritis, IGANCT05797610

TargetBeta

“A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients With Primary IgA Nephropathy at High Risk of Progression”study text, read by Claude · the study

Other programs on CFB

ProgramCompanyFurthest phaseStudies
iptacopanruleNovartisphase 325
HRS-5965Jiangsu HengRui Medicinephase 314
NTQ5082ruleSino Biopharmaceuticalphase 36
FXS6837Fosun Pharmaphase 34
HS-10542Hansoh Pharmaceutical Groupphase 23
FWY003Novartisphase 21
SAR446597Sanofiphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05797610Glomerulonephritis, IGA · United States, Argentina, Australia and more3Active, not recruitingMay 25, 2028459

How it is read

Names in the registry

  • “Sefaxersen (RO7434656)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.